Halozyme Therapeutics | HALO - Los Gastos De Explotación





Los Gastos De Explotación Cambio Fecha
Acadia Pharmaceuticals USD 270.12M 2.55M 2026-06
Agios Pharmaceuticals USD 130.77M 10.77M 2026-03
Alnylam Pharmaceuticals USD 1.06B 160.97M 2026-06
Amarin USD 51.48M 113K 2025-12
Amgen USD 11.69B 6.9B 2026-06
Baxter International USD 2.68B 3.36B 2026-06
Cara Therapeutics USD 7.05M 1.11M 2026-03
Cytokinetics USD 207.8M 7.22M 2026-06
DBV Technologies USD 47.9M 2.2M 2026-03
Eli Lilly USD 10.52B 496M 2026-06
Halozyme Therapeutics USD 193.34M 1.15M 2026-06
Intrexon USD 61.56M 26.1M 2024-06
Ionis Pharmaceuticals USD 370.24M 6.24M 2026-06
MannKind USD 110.21M 690K 2026-06
Minerva Neurosciences USD 4.52M 155.46K 2024-12
Nektar Therapeutics USD 49.12M 8.22M 2026-03
Pfizer USD 85.19B 4.91B 2026-06
Rigel Pharmaceuticals USD 117.61M 35.67M 2025-09
United Therapeutics USD 6.4B 499.2M 2026-06
Vanda Pharmaceuticals USD -1.14B 1.6B 2025-12